• Home
• People
• Bio
• Terry Ponich

Terry Ponich

Selected Publications

L. Kwapisz, J. Gregor, N. Chande, B. Yan, T. Ponich, M. Mosli. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Jan 2017.

Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, Chande N, Mosli M, Kim RB. Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel Disease. Jul 1, 2016.

Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, Chande N, Mosli M, Kim RB. Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel Disease. Jan 1, 2016.

Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, Mennill PW, Barnett W, Bax K, Ponich T, Howard J, Tirolese A, Lannigan R, Gregor J. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Jul 1, 2015.

Sandhu A, Mosli M, Yan B, Wu T, Gregor J, Chande N, Ponich T, Beaton M, Rahman A. Self-Screening for Malnutrition Risk in Outpatient Inflammatory Bowel Disease Patients Using the Malnutrition Universal Screening Tool (MUST). Jan 28, 2015.

Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG,
Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Jul 1, 2014.

Teriaky A, Gregor J, Yan B, Ponich T, Chande N, Mosli M. The safety and efficacy of adalimumab in patients with Crohn’s disease: the experience of a single Canadian tertiary care centre. Mar 1, 2014.

Wilson A, Delport J, Ponich T. Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? Jan 1, 2014.

Sey MS, Gregor J, Chande N, Ponich T, Bhaduri M, Lum A, Zaleski W, Yan B. Transcutaneous bowel sonography for inflammatory bowel disease is sensitive and specific when performed in a nonexpert low-volume North American center. Aug 1, 2013.

Wilson A, Patel V, Chande N, Ponich T, Urquhart B, Asher L, Choi Y, Tirona R, Kim RB, Gregor JC. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease. Feb 1, 2013.

Parikh, A., Leach, T., Wyant, T., Scholz, C., Sankoh, S., Mould, D. R., Ponich, T., Fox, I. and Feagan, B. G. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 dose-ranging Study. Jan 2011.

Roth LS, Chande N, Ponich T, Roth ML, Gregor J. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. Jan 14, 2010.